直接口服抗凝剂时代的血栓形成倾向检测。
Thrombophilia testing in the era of direct oral anticoagulants.
作者信息
Darlow Jennifer, Mould Holly
机构信息
Manchester Royal Infirmary, Manchester, UK
equal first authors.
出版信息
Clin Med (Lond). 2021 Sep;21(5):e487-e491. doi: 10.7861/clinmed.2020-1008. Epub 2021 Sep 7.
Abstract
Venous thromboembolism (VTE) is increasingly recognised in primary and secondary care practice. The arrival of direct oral anticoagulants (DOACs) has made the management of VTE easier and more convenient. Some patients established on DOACs may need screening for underlying thrombophilias as certain thrombophilic conditions are known to confer a higher thrombosis risk, although the guidelines for when and how to test for a thrombophilia, especially in a patient taking a DOAC, are unclear. This literature review aims to examine when thrombophilia screening should take place in a patient already taking a DOAC, the effect of DOACs on thrombophilia tests, and analyse whether DOACs are safe and effective in both inherited and acquired thrombophilias.
摘要
静脉血栓栓塞症（VTE）在初级和二级医疗实践中越来越受到重视。直接口服抗凝剂（DOACs）的出现使VTE的管理变得更加容易和便捷。一些正在使用DOACs进行治疗的患者可能需要筛查潜在的血栓形成倾向，因为已知某些血栓形成倾向状况会带来更高的血栓形成风险，尽管关于何时以及如何检测血栓形成倾向的指南并不明确，尤其是对于正在服用DOACs的患者。这篇文献综述旨在研究在已经服用DOACs的患者中何时应进行血栓形成倾向筛查、DOACs对血栓形成倾向检测的影响，并分析DOACs在遗传性和获得性血栓形成倾向中是否安全有效。
相似文献
1
Thrombophilia testing in the era of direct oral anticoagulants.直接口服抗凝剂时代的血栓形成倾向检测。
Clin Med (Lond). 2021 Sep;21(5):e487-e491. doi: 10.7861/clinmed.2020-1008. Epub 2021 Sep 7.
2
Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis.直接口服抗凝剂在静脉血栓栓塞和血栓形成倾向患者中的应用：系统评价和荟萃分析。
J Thromb Haemost. 2019 Apr;17(4):645-656. doi: 10.1111/jth.14398. Epub 2019 Feb 25.
3
Direct Oral Anticoagulants in Select Patients With Hypercoagulable Disorders.直接口服抗凝剂在伴有高凝状态的选择性患者中的应用。
Ann Pharmacother. 2021 Jul;55(7):891-901. doi: 10.1177/1060028020968551. Epub 2020 Oct 26.
4
Inherited Thrombophilia in the Era of Direct Oral Anticoagulants.直接口服抗凝剂时代的遗传性血栓形成倾向。
Int J Mol Sci. 2022 Feb 5;23(3):1821. doi: 10.3390/ijms23031821.
5
Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review.有血栓形成倾向、抗磷脂综合征或不常见部位静脉血栓形成患者中直接口服抗凝剂的应用：叙述性综述。
Blood Rev. 2018 Jul;32(4):272-279. doi: 10.1016/j.blre.2018.01.002. Epub 2018 Apr 20.
6
Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants: comparison between patients with major congenital thrombophilia versus non-thrombophilic patients.直接口服抗凝剂用于静脉血栓栓塞症的二级预防：伴主要先天性血栓形成倾向与非血栓形成倾向患者的比较。
Intern Emerg Med. 2022 Jun;17(4):1081-1085. doi: 10.1007/s11739-021-02917-3. Epub 2022 Jan 11.
7
Thrombophilia testing in the real-world clinical setting of thrombosis centres taking part in the Italian Start 2-Register.血栓形成中心参与意大利 Start 2-Register 的真实临床环境中的血栓形成倾向检测。
Blood Transfus. 2021 May;19(3):244-252. doi: 10.2450/2021.0262-20. Epub 2021 Jan 27.
8
Direct Oral Anticoagulants in Patients with Thrombophilia: Challenges in Diagnostic Evaluation and Treatment.血栓形成倾向患者的直接口服抗凝剂：诊断评估和治疗中的挑战
Adv Clin Exp Med. 2016 Nov-Dec;25(6):1321-1330. doi: 10.17219/acem/65853.
9
Diagnosis and management of congenital thrombophilia in the era of direct oral anticoagulants.直接口服抗凝剂时代先天性血栓形成倾向的诊断与治疗。
Thromb Res. 2020 Jan;185:72-77. doi: 10.1016/j.thromres.2019.11.008. Epub 2019 Nov 12.
10
DOAC-Remove abolishes the effect of direct oral anticoagulants on activated protein C resistance testing in real-life venous thromboembolism patients.DOAC-Remove 消除了直接口服抗凝剂对真实静脉血栓栓塞患者活化蛋白 C 抵抗检测的影响。
Clin Chem Lab Med. 2020 Feb 25;58(3):430-437. doi: 10.1515/cclm-2019-0650.
引用本文的文献
1
Etiology and Risk Factors for Splanchnic Vein Thrombosis in Non-Cirrhotic, Non-Neoplastic Patients: A Narrative Review.非肝硬化、非肿瘤患者内脏静脉血栓形成的病因及危险因素：一项叙述性综述
Medicina (Kaunas). 2025 May 21;61(5):933. doi: 10.3390/medicina61050933.
2
Comparing the Effect of DOAC-Stop and DOAC-Remove on Apixaban, Rivaroxaban and Dabigatran Prior to Thrombophilia and Lupus Testing.比较 DOAC 停药和 DOAC 去除对血栓形成倾向和狼疮检测前依度沙班、利伐沙班和达比加群的影响。
Br J Biomed Sci. 2024 Oct 29;81:13359. doi: 10.3389/bjbs.2024.13359. eCollection 2024.
3
The Etiology of the Thrombotic Phenomena Involved in the Process of Coronary Artery Disease-What Is the Role of Thrombophilic Genes in the Development of This Pathology?血栓形成现象在冠状动脉疾病过程中的病因学——血栓形成倾向基因在这种病理发展中的作用是什么？
Int J Mol Sci. 2024 May 11;25(10):5228. doi: 10.3390/ijms25105228.
4
Risk factors and incidence of central venous access device-related thrombosis in hospitalized children: a systematic review and meta-analysis.住院儿童中心静脉通路装置相关血栓形成的危险因素及发生率：一项系统评价和荟萃分析
Pediatr Res. 2024 Dec;96(7):1568-1593. doi: 10.1038/s41390-024-03225-0. Epub 2024 May 17.
5
Stroke Thrombectomy and Right Atrial Clot Aspiration in 29 Year Old Woman.29岁女性的中风血栓切除术及右心房血块抽吸术
Neurohospitalist. 2024 Jan;14(1):95-98. doi: 10.1177/19418744231200052. Epub 2023 Sep 1.
6
Antithrombin Therapy: Current State and Future Outlook.抗凝血酶治疗：现状与未来展望。
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231205279. doi: 10.1177/10760296231205279.
7
The methods for removal of direct oral anticoagulants and heparins to improve the monitoring of hemostasis: a narrative literature review.去除直接口服抗凝剂和肝素以改善止血监测的方法：一篇叙述性文献综述
Thromb J. 2023 May 19;21(1):58. doi: 10.1186/s12959-023-00501-7.
8
Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants.抗凝期间的狼疮抗凝物检测，包括直接口服抗凝剂。
Res Pract Thromb Haemost. 2022 Mar 15;6(2):e12676. doi: 10.1002/rth2.12676. eCollection 2022 Feb.
本文引用的文献
1
Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interference.活化蛋白 C 抵抗的实验室检测：利伐沙班诱导的干扰及对andexanet alfa 和 DOAC Stop 中和干扰的比较评估。
Clin Chem Lab Med. 2020 Jul 28;58(8):1322-1331. doi: 10.1515/cclm-2019-1160.
2
Thrombosis among 1537 patients with JAK2 -mutated myeloproliferative neoplasms: Risk factors and development of a predictive model.1537 例 JAK2 突变骨髓增殖性肿瘤患者的血栓形成：危险因素和预测模型的建立。
Cancer Med. 2020 Mar;9(6):2096-2105. doi: 10.1002/cam4.2886. Epub 2020 Jan 28.
3
Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47-58): use of direct acting oral anticoagulants.《英国血液学学会抗磷脂综合征调查与管理指南（2012年）》（《英国血液学杂志》2012年；157卷：47 - 58页）补遗：直接口服抗凝剂的使用
Br J Haematol. 2020 Apr;189(2):212-215. doi: 10.1111/bjh.16308. Epub 2020 Jan 13.
4
Current Controversies in Lupus Anticoagulant Detection.狼疮抗凝物检测中的当前争议
Antibodies (Basel). 2016 Dec 2;5(4):22. doi: 10.3390/antib5040022.
5
DOAC-Remove abolishes the effect of direct oral anticoagulants on activated protein C resistance testing in real-life venous thromboembolism patients.DOAC-Remove 消除了直接口服抗凝剂对真实静脉血栓栓塞患者活化蛋白 C 抵抗检测的影响。
Clin Chem Lab Med. 2020 Feb 25;58(3):430-437. doi: 10.1515/cclm-2019-0650.
6
The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants.直接口服抗凝剂治疗的静脉血栓栓塞患者血浆样本中 DOAC-Stop 对狼疮抗凝物检测的影响。
Clin Chem Lab Med. 2019 Aug 27;57(9):1374-1381. doi: 10.1515/cclm-2018-1197.
7
Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis.直接口服抗凝剂在静脉血栓栓塞和血栓形成倾向患者中的应用：系统评价和荟萃分析。
J Thromb Haemost. 2019 Apr;17(4):645-656. doi: 10.1111/jth.14398. Epub 2019 Feb 25.
8
Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives.狼疮抗凝物（LA）在服用直接口服抗凝剂（DOACs）患者中的实验室检测：潜在的假阳性和假阴性。
Pathology. 2019 Apr;51(3):292-300. doi: 10.1016/j.pathol.2018.11.008. Epub 2019 Jan 18.
9
Danger of false negative (exclusion) or false positive (diagnosis) for 'congenital thrombophilia' in the age of anticoagulants.抗凝时代“先天性血栓形成倾向”假阴性（漏诊）或假阳性（误诊）的危险。
Clin Chem Lab Med. 2019 May 27;57(6):873-882. doi: 10.1515/cclm-2018-1041.
10
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.美国血液学会 2018 年静脉血栓栓塞症管理指南：抗凝治疗的最佳管理。
Blood Adv. 2018 Nov 27;2(22):3257-3291. doi: 10.1182/bloodadvances.2018024893.
Zotero 插件